The Manufacturers Life Insurance Company Acquires 657 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

The Manufacturers Life Insurance Company grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 3.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 18,473 shares of the company’s stock after acquiring an additional 657 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in TransMedics Group were worth $2,900,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in TransMedics Group during the 2nd quarter valued at $47,000. USA Financial Formulas bought a new stake in shares of TransMedics Group during the 3rd quarter valued at about $55,000. J.Safra Asset Management Corp increased its position in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the period. Signaturefd LLC raised its stake in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after buying an additional 316 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $68.26 on Friday. TransMedics Group, Inc. has a 1 year low of $66.10 and a 1 year high of $177.37. The firm’s 50-day moving average is $103.61 and its 200 day moving average is $133.90. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of 72.62 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.12) EPS. Sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,042 shares of company stock worth $3,563,985. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TMDX. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. lowered their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, December 3rd. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.